查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1866216

全球季节性情绪障碍治疗市场成长、规模和趋势分析（治疗方法、疾病类型和最终用户划分）—区域展望、竞争策略和细分市场预测（至 2034 年）

Global Seasonal Affective Disorder Therapeutics Market Growth, Size, Trends Analysis - By Treatment Type, By Disorder Type, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 259 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计到 2034 年，全球季节性情感障碍治疗市场规模将达到 13.3853 亿美元，复合年增长率为 4.98%。

季节性情感障碍（SAD）是一种忧郁症，多发于特定季节，尤其是在秋季和冬季，此时自然光照减少。治疗方法包括光疗、抗忧郁症、心理治疗和生活方式调整，所有这些方法都旨在改善情绪和精力水平。近年来，医疗产业致力于开发创新且以患者为中心的治疗方法，以提高治疗的可及性和有效性。

阻碍因素：儘管需求不断增长，季节性情感障碍的广泛治疗仍面临许多障碍。抗忧郁症的副作用和黑框警告会降低患者的依从性，并削弱长期疗效。中低收入国家对此疾病的认知度低和诊断不足也阻碍了患者快速获得治疗。支付者对使用迷幻药和氯胺酮等药物的非标籤药物治疗诊所的限制进一步阻碍了替代疗法的广泛应用。最后，用于製造LED灯箱的稀土元素的供应不稳定，威胁着生产的稳定性和市场供应。

本报告调查了全球季节性情感障碍治疗市场，并提供了市场概况、市场影响因素和市场机会分析、市场规模趋势和预测、按各个细分市场、地区/主要国家进行的详细分析、竞争格局以及主要企业的概况。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场动态

  • 驱动因素、阻碍因素、机会与挑战分析

第五章 市场变数与展望

  • SWOT分析
  • PESTEL 分析
  • 波特五力分析
  • 热图分析

第六章 竞争情势

  • 製造地、销售区域和产品类型的分布
  • 併购、合作、产品发布与协作

7. 全球季节性情感障碍治疗市场（依治疗类型划分）

  • 药物
    • 选择性血清素再回收抑制剂（SSRIs）
    • 去甲肾上腺素多巴胺再回收抑制剂（NDRIs）
    • 单胺氧化酵素抑制剂（MAOIs）
    • 其他的
  • 治疗
    • 光疗
    • 心理治疗

8. 全球季节性情感障碍治疗市场（依疾病类型划分）

  • 秋季和冬季季节性情感障碍
  • 春夏季节性情感障碍

9. 全球季节性情感障碍治疗市场（以最终用户划分）

  • 医院
  • 专科诊所
  • 居家照护
  • 其他的

第十章 全球季节性情感性疾患治疗市场

  • 全球市场规模和市场份额

11. 全球季节性情感障碍治疗市场（依地区划分）

  • 亚太地区
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他的
  • 欧洲
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 埃及
    • 摩洛哥
    • 奈及利亚
    • 其他的
  • 北美洲
    • 加拿大
    • 墨西哥
    • 美国
  • 拉丁美洲
    • 阿根廷
    • 巴西
    • 其他的

第十二章 公司概况

  • AbbVie
  • Amen Clinics
  • Bausch Health Companies
  • Cleveland Clinic
  • Eli Lilly and Company
  • GlaxoSmithKlinz
  • Henry Schein
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • Mayo Clinic
  • Novartis
  • 其他的

第十三章 结论

第十四章简称列表

第十五章参考链接

简介目录
Product Code: HLCA25317

Global Seasonal Affective Disorder Therapeutics Market Introduction and Overview

According to SPER market research, 'Global Seasonal Affective Disorder Therapeutics Market Size- By Treatment Type, By Diagnosis Type, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' states that the Global Seasonal Affective Disorder Therapeutics Market is predicted to reach 1338.53 million by 2034 with a CAGR of 4.98%.

Seasonal Affective Disorder (SAD) is a type of depression that occurs during specific seasons, most notably fall and winter, when natural sunlight is reduced. Light treatment, antidepressant medicines, psychotherapy, and lifestyle changes are all used to treat SAD and improve mood and energy levels. The healthcare and mental health industries are increasingly focusing on creative and patient-friendly techniques to improve treatment accessibility and effectiveness.

Restraints: Despite rising demand, various barriers prevent the widespread use of Seasonal Affective Disorder treatments. Side effects and black-box warnings on antidepressants frequently reduce patient adherence, lowering long-term effectiveness. Low awareness and underdiagnosis in low- and middle-income countries impede prompt treatment access. Furthermore, payor restrictions for off-label psychedelic or ketamine-based clinics limit the expansion of alternate therapy pathways. Another issue comes with LED light boxes, where rare-earth element supply issues jeopardize production stability and availability.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Treatment Type, By Disorder Type, By End User

Regions covered North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered AbbVie, Amen Clinics, Bausch Health Companies, Cleveland Clinic, Eli Lilly and Company, GlaxoSmithKline, Henry Schein, Johnson & Johnson (Janssen Pharmaceuticals), Mayo Clinic, Novartis.

Global Seasonal Affective Disorder Therapeutics Market Segmentation:

By Treatment Type: Based on the Treatment Type, Global Seasonal Affective Disorder Therapeutics Market is segmented as; Medications, Therapy.

By Disorder Type: Based on the Disorder Type, Global Seasonal Affective Disorder Therapeutics Market is segmented as; Fall & winter SAD, Spring & summer SAD.

By End User: Based on the End User, Global Seasonal Affective Disorder Therapeutics Market is segmented as; Hospitals, Specialty clinics, Homecare setting, Other end user.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Table of Contents

1.Introduction

  • 1.1.Scope of the report
  • 1.2.Market segment analysis

2.Research Methodology

  • 2.1.Research data source
    • 2.1.1.Secondary Data
    • 2.1.2.Primary Data
    • 2.1.3.SPERs internal database
    • 2.1.4.Premium insight from KOLs
  • 2.2.Market size estimation
    • 2.2.1.Top-down and Bottom-up approach
  • 2.3.Data triangulation

3.Executive Summary

4.Market Dynamics

  • 4.1.Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1.Drivers
    • 4.1.2.Restraints
    • 4.1.3.Opportunities
    • 4.1.4.Challenges

5.Market variable and outlook

  • 5.1.SWOT Analysis
    • 5.1.1.Strengths
    • 5.1.2.Weaknesses
    • 5.1.3.Opportunities
    • 5.1.4.Threats
  • 5.2.PESTEL Analysis
    • 5.2.1.Political Landscape
    • 5.2.2.Economic Landscape
    • 5.2.3.Social Landscape
    • 5.2.4.Technological Landscape
    • 5.2.5.Environmental Landscape
    • 5.2.6.Legal Landscape
  • 5.3.PORTERs Five Forces
    • 5.3.1.Bargaining power of suppliers
    • 5.3.2.Bargaining power of buyers
    • 5.3.3.Threat of Substitute
    • 5.3.4.Threat of new entrant
    • 5.3.5.Competitive rivalry
  • 5.4.Heat Map Analysis

6.Competitive Landscape

  • 6.1.Global Seasonal Affective Disorder Therapeutics Market Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Seasonal Affective Disorder Therapeutics Market

7.Global Seasonal Affective Disorder Therapeutics Market, By Treatment Type (USD Million) 2021-2034

  • 7.1.Medication
    • 7.1.1.Selective serotonin reuptake inhibitors (SSRI)
    • 7.1.2.Norepinephrine-dopamine reuptake inhibitor (NDRI)
    • 7.1.3.Monoamine oxidase inhibitor (MAOI)
    • 7.1.4.Other drug types
  • 7.2.Therapy
    • 7.2.1.Light therapy
    • 7.2.2.Psychotherapy

8.Global Seasonal Affective Disorder Therapeutics Market, By Disorder Type (USD Million) 2021-2034

  • 8.1.Fall & winter SAD
  • 8.2.Spring & summer SAD

9.Global Seasonal Affective Disorder Therapeutics Market, By End User (USD Million) 2021-2034

  • 9.1.Hospitals
  • 9.2.Specialty clinics
  • 9.3.Homecare setting
  • 9.4.Other end use

10.Global Seasonal Affective Disorder Therapeutics Market, (USD Million) 2021-2034

  • 10.1.Global Seasonal Affective Disorder Therapeutics Market Size and Market Share

11.Global Seasonal Affective Disorder Therapeutics Market, By Region, (USD Million) 2021-2034

  • 11.1.Asia-Pacific
    • 11.1.1.Australia
    • 11.1.2.China
    • 11.1.3.India
    • 11.1.4.Japan
    • 11.1.5.South Korea
    • 11.1.6.Rest of Asia-Pacific
  • 11.2.Europe
    • 11.2.1.France
    • 11.2.2.Germany
    • 11.2.3.Italy
    • 11.2.4.Spain
    • 11.2.5.United Kingdom
    • 11.2.6.Rest of Europe
  • 11.3.Middle East and Africa
    • 11.3.1.Kingdom of Saudi Arabia
    • 11.3.2.United Arab Emirates
    • 11.3.3.Qatar
    • 11.3.4.South Africa
    • 11.3.5.Egypt
    • 11.3.6.Morocco
    • 11.3.7.Nigeria
    • 11.3.8.Rest of Middle-East and Africa
  • 11.4.North America
    • 11.4.1.Canada
    • 11.4.2.Mexico
    • 11.4.3.United States
  • 11.5.Latin America
    • 11.5.1.Argentina
    • 11.5.2.Brazil
    • 11.5.3.Rest of Latin America

12.Company Profile

  • 12.1.AbbVie
    • 12.1.1.Company details
    • 12.1.2.Financial outlook
    • 12.1.3.Product summary
    • 12.1.4.Recent developments
  • 12.2.Amen Clinics
    • 12.2.1.Company details
    • 12.2.2.Financial outlook
    • 12.2.3.Product summary
    • 12.2.4.Recent developments
  • 12.3.Bausch Health Companies
    • 12.3.1.Company details
    • 12.3.2.Financial outlook
    • 12.3.3.Product summary
    • 12.3.4.Recent developments
  • 12.4.Cleveland Clinic
    • 12.4.1.Company details
    • 12.4.2.Financial outlook
    • 12.4.3.Product summary
    • 12.4.4.Recent developments
  • 12.5.Eli Lilly and Company
    • 12.5.1.Company details
    • 12.5.2.Financial outlook
    • 12.5.3.Product summary
    • 12.5.4.Recent developments
  • 12.6.GlaxoSmithKlinz
    • 12.6.1.Company details
    • 12.6.2.Financial outlook
    • 12.6.3.Product summary
    • 12.6.4.Recent developments
  • 12.7.Henry Schein
    • 12.7.1.Company details
    • 12.7.2.Financial outlook
    • 12.7.3.Product summary
    • 12.7.4.Recent developments
  • 12.8.Johnson & Johnson (Janssen Pharmaceuticals)
    • 12.8.1.Company details
    • 12.8.2.Financial outlook
    • 12.8.3.Product summary
    • 12.8.4.Recent developments
  • 12.9.Mayo Clinic
    • 12.9.1.Company details
    • 12.9.2.Financial outlook
    • 12.9.3.Product summary
    • 12.9.4.Recent developments
  • 12.10.Novartis
    • 12.10.1.Company details
    • 12.10.2.Financial outlook
    • 12.10.3.Product summary
    • 12.10.4.Recent developments
  • 12.11.Others

13.Conclusion

14.List of Abbreviations

15.Reference Links